Eli Lilly Exec Says Seeing Out of Pocket Payments for Obesity Drug in US

A top Eli Lilly (LLY.N), opens new tab executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.Patrik Jonsson, President of Lilly Diabetes and Obesity, speaking at a Goldman…[#item_full_content]

Related articles

You may also be interested in

Headline

Never Miss A Story

Get our Weekly recap with the latest news, articles and resources.
Cookie policy

We use our own and third party cookies to allow us to understand how the site is used and to support our marketing campaigns.